ScripThe development path for better idiopathic pulmonary fibrosis (IPF) treatments is strewn with failures but Bristol Myers Squibb Company is hoping for a more successful journey on the back of positiv
In VivoThe pace of decline in biopharma venture capital investment over the past year has been striking: after an impressive first quarter in 2022, when biopharma companies raised $11.9bn, the amount of VC f